MBRX MBRX

Moleculin Biotech Stock Price

FREE MBRX REPORT

1.29
0.03 (2.38%)
Upgrade to Real-Time
Afterhours (Closed)
1.29
Volume 63,772
Bid Price 1.28
Ask Price 1.31
News -
Day High 1.29

Low
0.817

52 Week Range

High
2.05

Day Low 1.25
Company Name Stock Ticker Symbol Market Type
Moleculin Biotech Inc MBRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 2.38% 1.29 16:30:00
Open Price Low Price High Price Close Price Prev Close
1.29 1.25 1.29 1.29 1.26
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
133 63,772 $ 1.26 $ 80,591 - 0.817 - 2.05
Last Trade Time Type Quantity Stock Price Currency
16:35:58 1 $ 1.31 USD

Period:

Draw Mode:

Moleculin Biotech Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 36.93M 28.63M 28.01M $ - $ - -0.59 -1.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 67.50k 3.10%

more financials information »

Moleculin Biotech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MBRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.271.321.221.2741,2520.021.57%
1 Month1.121.351.021.1866,4010.1715.18%
3 Months1.021.510.8171.25107,7310.2726.47%
6 Months1.661.850.8171.30101,460-0.37-22.29%
1 Year1.542.050.8171.4193,021-0.25-16.23%
3 Years0.918.780.3231.881,441,3610.3841.76%
5 Years1.978.780.3231.881,172,632-0.68-34.52%

Moleculin Biotech Description

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.